JAZZ · Jazz Pharmaceuticals plc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 3, 2026TL;DR. Jazz delivered record Q2 2026 revenue of $1.21B (+16% YoY) with broad-based growth across the portfolio, raised full-year 2026 revenue guidance to $4.60–$4.75B, and is prepared to launch Ziihera in 1L HER2+ GEA immediately following the August 25, 2026 PDUFA date, with a second interim OS readout from HERIZON-GEA-01 expected in 3Q26.
- + Record Q2 revenue of $1.21B with 16% YoY growth driven by 32% oncology, 13% Xywav, and 16% Epidiolex growth
- − Planning to submit labeling supplement in 3Q26 to remove Zepzelca's second-line indication, which may accelerate erosion of that business
- − Modeyso Phase 3 ACTION OS interim analysis pushed to 1H27 from prior expectations
- − Non-GAAP gross margin declined YoY (92.1% vs 92.7%) due to higher third-party royalties on Zepzelca and Modeyso
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JAZZ
this stock
Jazz Pharmaceuticals plc
|
$15.45B | +36.7% | +8.8% | 16.3 | 7.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +16.2% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -2.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JAZZ | -3.4% | -7.3% | +18.6% | -7.3% | +36.7% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | -2.2% | -6.9% | +5.5% | -6.9% | +24.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.